Propranolol: A "Pick and Roll" Team Player in Benign Tumors and Cancer Therapies.

ABSTRACT: Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors,

SUBMITTER: Albinana V 

PROVIDER: S-EPMC9369479 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature